Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Avalon GloboCare Corp. (AVCO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9488-0.0312 (-3.18%)
At close: 04:00PM EST
0.9280 -0.02 (-2.19%)
After hours: 06:02PM EST
Advertisement

Avalon GloboCare Corp.

4400 Route 9 South
Suite 3100
Freehold, NJ 07728
United States
732 780 4400
http://www.avalon-globocare.com

Sector(s)Healthcare
IndustryMedical Care Facilities
Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Dr. David K. JinCEO, Pres & Director360kN/A1968
Ms. Luisa IngargiolaChief Financial Officer350kN/A1968
Ms. Meng LiCOO, Sec. & Director340kN/A1978
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. In addition, the company develops proprietary diagnostic and therapeutic products leveraging exosome technology; and provides development services for hospitals. The company has a strategic partnership with Weill Cornell Medical College to co-develop bio-production and standardization procedures for chimeric antigen receptor (CAR)-T Therapy; GensKey Medical Technology Co. Ltd. to co-develop and commercialize point-of-care, rapid detection antibody tests to identify whether a patient has been exposed to and has developed antibodies against SARS-CoV-2; GE Healthcare to enhance standardized automation and bio-production for cellular medicines; and HydroPeptide, LLC to co-develop and commercialize various clinical-grade, exosome-based cosmeceutical and orthopedic products, as well as research agreement with Massachusetts Institute of Technology to develop CAR technology. It also has a collaboration agreement with the UPMC Hillman Cancer Center to advance the clinical development and production of CAR therapies using FLASH CAR technology. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.

Corporate Governance

Avalon GloboCare Corp.’s ISS Governance QualityScore as of June 1, 2021 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement